Treating B-Cell Lymphomas: Novel Agents and the Evolving State of Practice

Access Activity

Overview / Abstract:

Over the last several decades, advances in non-Hodgkin lymphoma (NHL) management have improved survival; however, relapse and the emergence of treatment-resistant NHL following standard therapy remain ongoing treatment challenges. With conventional therapy for B-cell NHL, response rates are suboptimal and many patients relapse, highlighting the need for novel treatments that address the risk of disease progression. Recently, several novel therapies—including small-molecule inhibitors of the B-cell receptor pathway and next-generation monoclonal antibody therapies—have emerged or advanced in clinical trials. These agents offer the potential to dramatically improve outcomes in some treatment-resistant patients.

This activity has been developed to help advanced-practice oncology professionals stay current on the newest targeted NHL therapies and the best strategies for their effective use, particularly in the management of patients with multidrug-resistant and relapsing NHL. Additionally, this activity reviews current best practices for detecting variations in the natural history of NHL over time with the goal of improving long-term outcomes.

Expiration

Apr 08, 2020

Discipline(s)

Nurse Practitioner , Physician CME, Physician Assistant CME

Format

Online

Credits / Hours

1

Accreditation

ACCME, ACPE

Presenters / Authors / Faculty

Barbara Barnes Rogers, CRNP, MN, AOCN, ANP-BC
Adult Hematology-Oncology Nurse Practitioner
Fox Chase Cancer Center at Temple University
Philadelphia, PA

Activity Specialities / Related Topics

Hematology, Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

This activity is supported by an educational grant from Celgene Corporation, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Keywords / Search Terms

RedMedEd RedMedEd, Horizon CME, WSPA, free CME, NHL, non-Hodgkin lymphoma, B-cell, small-molecule inhibitors, b-cell receptor pathway, monoclonal antibody therapies, NHL therapies, treatment resistant NHL, CAR-T Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map